Top Ten most popular articles on Pharmafile.com this week

pharmafile | November 24, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing pharma, top ten 

As Friday comes round again, this week saw some of the biggest news of the year: Amsterdam is the new home of the EMA after the agency’s HQ was forced to move from its London home as a result of Brexit. The decision was shockingly decided by random lottery after becoming locked in a tie with Milan.

Elsewhere, the first-ever European biosimilar approval of Roche’s immunotherapy Herceptin has been passed, setting off a spark in the region that is sure to lead to close competition as others race to bring their own versions to market.

And just in time for the holidays, Teva has announced a massive staff cut, and it’s rumoured that up to 25% of all Israel-based staff could face the axe – a staggering 6,860 employees.

Check out the week’s ten most popular articles on Pharmafile.com now!

10. Boehringer offers its molecules to the scientific community via new platform

Boehringer Ingelheim has unveiled opnME.com, a centralised platform which makes available selected pre-clinical molecules from its portfolio for free, accessible for non-clinical investigation by scientists worldwide.

9. Acorda scraps Parkinson’s drug after five trial deaths

Acorda Therapeutics has announced that it is terminate development of its Parkinson’s therapy tozadenant after five deaths were reported as a result of trialling the drug.

8. Roche unveils strong combination treatment data in lung cancer

Roche has unveiled new Phase 3 efficacy data which showed strong findings for its immunotherapy Tecentriq in combination with Avastin and chemotherapy in the treatment of lung cancer.

7. Drinking three cups of coffee found to hold health benefits

In good news for coffee drinkers, drinking three to four cups of coffee was found to lower the risk of certain cancers, diabetes-risk, liver disease and dementia. Researchers concluded that coffee is “more likely to benefit health than to harm it”, after collating a number of studies together.

6. And the winner is…Amsterdam takes EMA HQ

In a decision that was likened to a penalty shoot-out, Amsterdam was announced as the winner of the race to become the new home of the EMA headquarters on a coin-toss decision.

5. Partnerships hold the key to making HIV history

Brian Woodfall, Global Head of Late Development, Infectious Diseases at Janssen, explains why a future without HIV can only be achieved if clinicians, academics, industry leaders and policymakers work together.

4. ‘Brain training’ found to reduce risk of dementia by 29%

In a 10-year study conducted at the Indiana University School of Medicine, researchers were able to observe a 29% reduced risk of developing dementia in patients who participated in a certain kind of computer-based training.

3. FDA approves first-ever two-drug HIV regimen, GSK’s Juluca

GlaxoSmithKline has announced that the FDA has awarded US marketing authorisation to the first two-drug regimen in the treatment of HIV.

2. Samsung Bioepis’ Ontruzant becomes first Herceptin biosimilar approved in Europe

Samsung Bioepis has announced that Ontruzant, the company’s biosimilar version of Roche’s Herceptin, has been awarded marketing authorisation in Europe by the EMA for the treatment of early breast cancer, metastatic breast cancer and metastatic gastric cancer.

1. Teva looks set to axe thousands of positions and a big name

With the appointment of Kåre Schultz, the company hopes that it can take some hard decisions to turn around the company – one of the first steps seems to be to fire a large number of staff.

Related Content

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …


Novartis acquires Chinook Therapeutics for $3.5bn

Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …

Latest content